ACCRUED LIABILITIES

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Payables and Accruals [Abstract]

ACCRUED LIABILITIES

NOTE 6. ACCRUED LIABILITIES

As of September 30, 2024 and December 31, 2023, the accrued liabilities of the Company consisted of the following:

	September 30, 2024		December 31, 2023
Product development	$	112,346	$	139,981
Accrued salaries, wages, and bonuses		8,736		8,889
Professional fees		114,068		584,810
Accrued restructuring costs (see Note 9)		—		301,645
Accrued franchise taxes		—		22,318
Patent costs		18,000		18,000
Total accrued expenses	$	253,150	$	1,075,643

ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6. ACCRUED LIABILITIES

As of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:

	December 31, 2023		December 31, 2022
Product development	$	139,981	$	195,104
Accrued salaries, wages, and bonuses		8,889		1,175,963
Professional fees		584,810		83,255
Accrued restructuring costs		301,645		—
Accrued franchise taxes		22,318		—
Patent costs		18,000		251,333
Total accrued expenses	$	1,075,643	$	1,705,655